GoAI
Get started
ClearPoint Neuro, Inc. logo

ClearPoint Neuro, Inc.

CLPT

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$15.39

+$0.20 · +1.32%

Aug 21, 4:00 PM ET

CLPT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

60

Fair Value

Momentum

60

Neutral

Sentiment

52

Mixed

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Joseph Michael Burnett
Listed since
May 22, 2012
Employees
172

Market position

Day range

Current $15.39

52-week range

Current $15.39

Open
$15.21
Previous close
$15.19
Volume
560.73K
0.84× average
Average volume
668.93K
Average daily volume
Market cap
461.54M USD
Beta
1.27
Market reference 1
50-day average
$15.7696
-2.41% below average
200-day average
$13.478
+14.19% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
399.66M USD
P/E (TTM)
-13.04×
P/B (TTM)
42.64×
P/S (TTM)
10.92×
EV / EBITDA
-19.16×
Earnings yield
-6.59%
Free cash flow yield
-6.31%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.61%
Operating margin
-73.42%
Net margin
-81.76%
Return on equity
-91.15%
Return on assets
-26.13%
Return on invested capital
-27.56%

Financial health

Debt / equity
5.93×
Current ratio
5.91×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends84%20%-45%-110%Gross margin, FY2021: 68.24%Gross margin, FY2022: 65.84%Gross margin, FY2023: 56.83%Gross margin, FY2024: 60.92%Gross margin, FY2025: 61.38%Operating margin, FY2021: -82.05%Operating margin, FY2022: -79.47%Operating margin, FY2023: -93.70%Operating margin, FY2024: -62.91%Operating margin, FY2025: -65.36%Net margin, FY2021: -88.41%Net margin, FY2022: -79.97%Net margin, FY2023: -92.21%Net margin, FY2024: -60.25%Net margin, FY2025: -69.08%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.24%. Gross margin FY2022 65.84%. Gross margin FY2023 56.83%. Gross margin FY2024 60.92%. Gross margin FY2025 61.38%. Operating margin FY2021 -82.05%. Operating margin FY2022 -79.47%. Operating margin FY2023 -93.70%. Operating margin FY2024 -62.91%. Operating margin FY2025 -65.36%. Net margin FY2021 -88.41%. Net margin FY2022 -79.97%. Net margin FY2023 -92.21%. Net margin FY2024 -60.25%. Net margin FY2025 -69.08%.

Income trends

Revenue

36.97M USD+17.78%

Operating income

−24.16M USD-22.37%

Net income

−25.54M USD-35.03%
Income trends across reported periods43.22M USD18.22M USD−6.79M USD−31.79M USDRevenue, FY2021: 16.3M USDRevenue, FY2022: 20.55M USDRevenue, FY2023: 23.96M USDRevenue, FY2024: 31.39M USDRevenue, FY2025: 36.97M USDOperating income, FY2021: −13.37M USDOperating income, FY2022: −16.33M USDOperating income, FY2023: −22.45M USDOperating income, FY2024: −19.75M USDOperating income, FY2025: −24.16M USDNet income, FY2021: −14.41M USDNet income, FY2022: −16.44M USDNet income, FY2023: −22.09M USDNet income, FY2024: −18.91M USDNet income, FY2025: −25.54M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 16.3M USD. Revenue FY2022 20.55M USD. Revenue FY2023 23.96M USD. Revenue FY2024 31.39M USD. Revenue FY2025 36.97M USD. Operating income FY2021 −13.37M USD. Operating income FY2022 −16.33M USD. Operating income FY2023 −22.45M USD. Operating income FY2024 −19.75M USD. Operating income FY2025 −24.16M USD. Net income FY2021 −14.41M USD. Net income FY2022 −16.44M USD. Net income FY2023 −22.09M USD. Net income FY2024 −18.91M USD. Net income FY2025 −25.54M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue36.97M USD31.39M USD23.96M USD20.55M USD16.3M USD
Cost of goods sold14.28M USD12.27M USD10.34M USD7.02M USD5.18M USD
Gross profit22.69M USD19.12M USD13.61M USD13.53M USD11.12M USD
Research and development13.9M USD12.39M USD11.71M USD10.89M USD9.28M USD
Selling, general, and administrative32.96M USD26.48M USD24.35M USD18.97M USD15.22M USD
Operating expenses46.86M USD38.87M USD36.06M USD29.86M USD24.5M USD
Interest income1.21M USD872K USD386K USD——
Interest expense2.39M USD——81K USD973K USD
Depreciation and amortization2.24M USD1.9M USD1.46M USD777K USD692K USD
Operating income−24.16M USD−19.75M USD−22.45M USD−16.33M USD−13.37M USD
Net income−25.54M USD−18.91M USD−22.09M USD−16.44M USD−14.41M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Corporate actions

Corporate action history

Stock split

Effective Jul 27, 2016

1:40

CLPT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CLPT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
12.76M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
11.02M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
5.18M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
4.02M
Weight
0.03%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
2.36M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
State Street SPDR S&P Kensho New Economies Composite ETF logoState Street SPDR S&P Kensho New Economies Composite ETFKOMP
Market value
1.85M
Weight
0.07%
AUM
2.71B USD
Expense ratio
0.20%
Price / 1D
$69.24+0.92%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.47M
Weight
0.10%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
State Street SPDR S&P Health Care Equipment ETF logoState Street SPDR S&P Health Care Equipment ETFXHE
Market value
1.43M
Weight
0.81%
AUM
176.38M USD
Expense ratio
0.35%
Price / 1D
$96.68+1.37%

Continue in GoAI

Research CLPT

research.disclaimer